INTRODUCTION

Over past several decades histologic profile of gastric polyps had changed altogether. Previous literature showed hyperplastic polyps (Hpp) very common outnumbering gastric fundic gland polyps (FGP) but enormous literature has accumulated in west beyond 2009 reflecting changing prevalence of gastric polyps, making FGP most common prevalent in west.1-5 Similarly Asian literature also start accumulating, showing FGP as most common type of gastric polyps.6,7 

On Esophagogastroduodenoscopy (EGD) FGP are small, sessile, glistening polyps lacking stalk, 5 to 10 mm in size
located usually in the proximal stomach. Surface color of FGP is translucent or hypermic and usually matches normal gastric mucosa. Endoscopic appearances are diagnostic with 89-90% accuracy. On microscopy, they have dilated glands and small cysts lined by gastric body mucosal cells like parietal and chief cells with insignificant inflammation. Associated gastric mucosal abnormalities like chronic inactive gastritis (C.I.G) and Helicobacter pylori (H. pylori) gastritis are also seen. Also FGP histologically can be easily differentiated from hyperplastic, adenomatous and other polyp like lesions.

It is believed that changing trend in FGP was due to aggressive use of proton pump inhibitors (PPI) in both western and Asian countries. Still researchers are trying to find out definitive histological, elaborative genetic and environmental differences between non-PPI and PPI associated FGP.

Our study has tried not only to look into current trends in prevalence of FGP but also endoscopic appearance and histologic pattern with respect to PPI use in those cases. Note of concomitant gastric histology was also made.

**METHODS AND MATERIALS**

Our study is a retrospective observational study. Medical records of patients who underwent esophagogastroduodenoscopy (EGD) in three gastroenterology centres between 2011 and 2019 were analysed at Noora super speciality Hospital, Kashmir, Northern India. Biopsy specimens of patients with FGP were reviewed by expert pathologists. Polyps were either biopsied or removed at time of endoscopy. Patients whose gastric biopsies were not assessed and properly graded as per the Sydney protocol were excluded from the study. PPI use was described on basis of doses and duration of PPI. PPI use was quantified as significant when Pantoprazole 40 mg per day or equivalent doses of other PPI was used four times or more per week for more than one year. Accordingly cases were grouped as PPI use group (with significant PPI use) and others as non-PPI use group. Histopathologic diagnoses of FGP were reviewed by expert pathologists and histopathologic features were analysed in all polyps for:

1. Type of cells in cyst epithelial lining like parietal cell, chief cell and other mucus cell.
2. Parietal cell and superficial foveolar epithelium changes (hyperplasia or protrusions of parietal cell and foveolar hyperplasia).
3. Glands for secretion and atrophy, epithelial cell changes like metaplasia or dysplasia.
4. Type of inflammation: chronic inflammatory infiltrate in lamina propria.
5. H. pylori infection.

**Inclusion criteria**
The inclusion criteria of the study were biopsy proven fundic gland polyps.

**Exclusion criteria**
The exclusion criteria were known malignancy, syndromic polyps on clinical grounds, cases in which gastric mucosal biopsies were not taken as per Sydney protocol.

**STATISTICS**

Statistical Analysis was conducted using SPSS version 22 for Windows (SPSS, Chicago, IL). Categorical variables estimation was done by using the chi-square or Fisher’s exact test., continuous data by t-test or the Mann-Whitney test and the Kruskal-Wallis test was used for multiple comparisons. Quantitative variables with a normal distribution were represented as mean values ± standard deviation and those with a non-normal distribution as median values (range). Significance levels were done two-sided and set to less than 0.05.

**ETHICAL CLEARANCE**

Permission for study was taken from Institutional review committee number/ date EC-1971 dated 7/1/2019. Identity of patients has not been disclosed while presenting this data.

**RESULT**

Of the 1800 cases with polyps, relative prevalence of FGP was 900 (50%). In cases with FGP synchronous polyp were seen in 7; Hpp in 4, adenomatous polyps in 2 and xanthomas in 1 case. Mean age of presentations was 51.42 years, lowest of 13 years and highest of 89 years, in which 579 (64.30%) were male and 321 (35.70%) female. Out of 900 FGP cases, 250 (27.80%) were smokers. The most frequent presenting complaint in cases with FGP was dyspepsia followed by anemia. PPI use was seen in 360(40%) of cases with FGP as in (Table 1).

The distribution, size and number of FGP in the stomach are given in Table 2. FGP were most common in the fundus and cardia. In PPI use group FGP were more frequent in fundus, smaller in size and less likely multiple than non-PPI group. However, none of these parameters reached significant level (p value > 0.05).

On histopathologic examination typical changes of FGP were noted in both non–PPI use and PPI use groups.
Parietal cell hyperplasia, parietal cell protrusion and foveolar hyperplasia varied in non–PPI use and PPI use groups but were insignificant (p value > 0.05) as in Table 3. In PPI use group cyst lining was more often lined by mixed type gastric cell and had Parietal cell protrusion on other hand in non-PPI use group cyst lining was more often lined by Oxynitric type gastric cell, more often had Parietal cell hyperplasia and Foveolar hyperplasia. However, none of these differences reached significant level (p-value ≤ 0.05) as shown in Table 3. H. pylori infections have similar frequency in both groups.

Background gastric mucosal histology was normal in majority of patients 543 (60.33%). One seventy-one (19%) have non-specific gastritis i.e., chronic inactive gastritis. H. pylori infection was seen in 7.5% FGP cases as in Table 3. H. pylori infection was seen in 7.5% FGP cases in our series. 

DISCUSSION

FGP are being increasingly reported because of speculative association with prolonged PPI therapy and some possible increase in frequency in recent decades.13 Reportedly these are commonest seen gastric polyps in studies from west.14,15 Study of gastric polyps of 5515 patients over a 20-year period, by Stolte et al in 1994,16 the incidence of FGP was 47%. In contrast, in 1996, Archimandritis from Greece1 reported that majority of polyps were Hpp (75%). In another study, by Morais DJ et al,2 2007 in Brazil, 70% of gastric polyps were Hpp and 16% were FGP. Deppisch et al.,17 in 1998 reported Hpp prevalence of 75% from the USA. However, Carmack et al.,18 in 2009 from United States published large series that reported dramatic change in relative prevalence of gastric polyps with FGP being most common type constituting 77%.

FGP constitutes 50% of 1800 gastric polyps in this study from Northern Indian population which is much higher than reported in the earlier literature in many parts of world.1,2,17 Given the possible widespread use of PPI in Northern India especially in Jammu Kashmir because of typical spicy dietary habits, over the counter use and free availability of PPI even in remote areas of this state, and probably increased H. pylori eradication in previous decade can be possible explanations.8,57

In 1989 FGP represented 17% of all gastric polyps in United States17 and 10% in France.18 The highest relative prevalence in the literature is 47% reported in a 20-year German study.16 In our series FGP made up 50% as mentioned above. FGP were possibly thought to be hemartoma and tend to arise in patients with H. pylori free stomachs and those receiving chronic PPIs treatment.1,3 In our study, only 7.6% have H. Pylori gastritis.

In our study, though 60% of cases had background histology of stomach normal, 19% of patients had chronic inactive gastritis (CIG) so it may be concluded that some forms of gastritis may increase the risk of gastric polyp, but this needs further research for validation.

The explanation for increasing trend of FGP may be the changing trend in PPI use and aggressive H. pylori treatment.13,18,21 Gastric polyps seem to be undergoing epidemiological change with the frequency of FGP increasing from 19% (15/80) to 77% (638/828) whereas Hpp decreased from 65% (52/80) to 15% (123/828).21 However, our study may be biased by the inclusion of more patients with dyspepsia and excessive PPIs use in the cases. More polyps were observed in adult males possibly because of more males in this study. However further research will is needed to look for gender susceptibility for polyp formation.

The mechanisms of rising prevalence of PPI use associated FGP may be genetic mutations or Hypergastrinemia. FGP genesis seems to be associated with prolonged PPI use.4,22,23

Table 1: Clinical profile of patients with FGP

| Clinical profile | n | percentage |
|------------------|---|------------|
| Males            | 579 | 64.30 |
| Females          | 321 | 35.70 |
| Smoker           | 250 | 27.80 |
| Symptoms and signs |   |   |
| Anemia           | 138 | 15.30 |
| Dyspepsia        | 568 | 63.20 |
| GERD             | 44  | 4.80  |
| FOBP             | 57  | 6.30  |
| Hematemesis      | 45  | 5     |
| Melena           | 48  | 5.30  |
| non-PPI use FGP  | 540 | 60    |
| No PPI use       | 396 | 43.60 |
| Occasional and less than 1 year | 144 | 26.60 |
| FGP associated with H. pylori | 360 | 40  |

GERD=Gastroesophageal reflux disease, FOBP=Fecal occult blood test positive, PPI=Proton pump inhibitors, FGP=Fundic gland polyps

Table 2: Relation of polyp location, size and number in non –PPI and PPI use groups

| Polyp variable | non-PPI use group | PPI use group | p-value |
|----------------|------------------|---------------|---------|
| Location of polyp |                 |               |         |
| Fundus/Cardia   | n=540 (68.51%)   | 253 (70.27%)  | 0.65    |
| Corpus          | 102 (18.88%)     | 67 (18.61%)   |         |
| Antrum          | 64 (11.85%)      | 38 (10.55%)   |         |
| Pylorus         | 4 (0.74%)        | 2 (0.55%)     |         |
| Size of polyp   |                 |               | 0.89    |
| 1-5 mm          | 402 (74.44%)     | 251 (69.72%)  |         |
| 6-10 mm         | 120 (22.22%)     | 96 (26.66%)   |         |
| Greater than 10 mm | 18 (3.33%) | 13 (3.6%)      |         |
| Number of polyps |                  |               | 0.99    |
| Single          | 27 (5%)          | 32 (8.88%)    |         |
| multiple        | 513 (95%)        | 329 (91.11%)  |         |
Cats et al in their study showed appearance of parietal cell protrusions, proliferation and glandular changes in patients on prolonged PPI therapy. These changes were seen in 18% of patients with early treatment and 86% of patients over one year. Jalving et al., have also shown somewhat similar results. However, this hypothesis of acid suppression with PPI leading to FGP is refuted by many researchers.

Hypergastrinemia, secondary to PPI chronic use can lead to parietal cell proliferation and hyperplasia. FGP can result from a dual mechanism of cellular proliferation and obstruction of glandular secretion flow, both related to PPI therapy.

Parietal cell changes like protrusion (60%) and hyperplasia (70%) were seen in cases with FGP in our study. These findings are the classical histological picture of FGP, with disorganized glands, which substantiated the classification of these lesions as hamartomatous in the past. Foveolar hyperplasia was observed in 40% of cases. True proliferative changes of foveolar epithelium related mostly to chronic active gastritis and H. pylori infection. Mucous plugs in glands and exfoliated cells in almost half (33%) of our sample provide support to the glandular flow obstruction hypothesis for FGP development.

Table 3: Histological features with comparison between non-PPI use group and PPI use group

| Pathologic features | non-PPI use group (n=396) | occasional PPI use group (n=144) | PPI use≥1 year group (n=360) | p-value |
|---------------------|---------------------------|----------------------------------|-----------------------------|---------|
| Cyst lining         |                           |                                  |                             | 0.99    |
| Mixed               | 204 (51.51%)              | 79 (54.86%)                      | 186 (51.66%)                |         |
| Oxyntic             | 150 (37.87%)              | 65 (45.13%)                      | 174 (48.33%)                |         |
| Parietal cell hyperplasia |                 |                                  |                             | 0.99    |
| Positive            | 303 (76.51%)              | 108 (75%)                        | 223 (61.94%)                |         |
| Negative            | 137 (34.59%)              | 36 (25%)                         | 137 (38.05%)                |         |
| Parietal cell protrusion |                      |                                  |                             | 0.32    |
| Positive focal      | 160 (40.4%)               | 61 (42.36%)                      | 162 (45%)                   |         |
| Positive diffuse    | 40 (10.1%)                | 12 (8.33%)                       | 38 (10.55%)                 |         |
| Negative            | 196 (49.49%)              | 71 (49.30%)                      | 160 (44.44%)                |         |
| Mucus plug          |                           |                                  |                             | 0.66    |
| Positive            | 127 (32.07%)              | 51 (35.41%)                      | 127 (35.27%)                |         |
| Negative            | 296 (77.92%)              | 93 (64.58%)                      | 233 (64.72%)                |         |
| Foveolar hyperplasia|                           |                                  |                             | 1.1     |
| Positive            | 160 (40.9%)               | 65 (45.13%)                      | 148 (41.11%)                |         |
| Negative            | 236 (59.09%)              | 79 (54.86%)                      | 212 (58.88%)                |         |
| H. pylori infection |                           |                                  |                             | 0.45    |
| Positive            | 26 (6.5%)                 | 14 (9.72%)                       | 28 (7.77%)                  |         |
| Negative            | 370 (93.43%)              | 130 (90.27%)                     | 332 (92.22%)                |         |

Table 4: Background gastric histology in cases with FGP

| Gastric histology               | n    | Percentage (%) |
|----------------------------------|------|----------------|
| Normal gastric mucosa            | 543  | 60.33%         |
| Chronic inactive gastritis       | 171  | 19%            |
| Reactive gastritis               | 78   | 8.7%           |
| Helicobacter pylori gastritis    | 68   | 7.5%           |
| Intestinal Metaplasia           | 37   | 4.1%           |
| Portal hypertensive gastritis    | 3    | 0.3%           |

H. Pylori = Helicobacter pylori

About half of polyps (50%) have cysts lined by parietal/chief cells only. Some of these cases showed tiny cysts in a background of hyperplastic and hypertrophied oxyntic mucosa with parietal cell protrusions, a histological change frequently described in non-polypoid gastric mucosa of chronic PPI users. Nevertheless, no specific morphologic markers were seen in PPI use FGP group in our study, as nearly similar architectural changes were noted in non-PPI use FGP group. These morphologic changes in oxyntic mucosa have also been recently linked to H. pylori chronic gastritis. The exact causative role of PPI therapy in oxyntic cell changes is still a under review.

H. pylori infection was detected in 68 (7.5%) of cases in our study which corroborates the well-known inverse association of FGP and this bacterium. Genta et al., found frequency of H. pylori infection in 0.5%. In fact, acquisition of H. pylori infection can cause regression of FGP.

Advance epithelial changes like metaplasia or beyond were not identified in any case in 900 fundic gland polyps examined in the study. So our study support paradigm of FGP being benign proliferative lesion, no matter it may show some Neoplastic-like features at molecular level.

We compared two groups endoscopically with respect to number, size and location of polyp to see any specific relation with PPI use associated FGP. There was no
significant statistical difference between number, size and location of polyps between PPI and non-PPI use group with p value ≥ 0.05 in all as in Table 2.

CONCLUSION

Our study describes the changing relative prevalence of different gastric polyps in a Northern Indian population. There is rising trend of FGP possibly signifying increasing PPI use and H. pylori eradication therapy. Parietal cell, glandular and epithelial changes were detected in PPI use and non-PPI use groups with insignificant differences.

ACKNOWLEDGEMENT

The authors take this opportunity to thank Department of Gastroenterology, Pathology and Medicine for their whole hearted support for this study

REFERENCES

1. Archimandritis A, Spiliadis C, Tzivras M, Vamvakousis B, Davaris P, Manika Z, et al. Gastric epithelial polyps: a retrospective endoscopic study of 12974 symptomatic patients. Ital J Gastroenterol. 1996;28(7):387-390.
2. Morais DJ, Yamanaka A, Zeitune JMR and Andreollo NA. Gastric polyps: A retrospective analysis of 26,000 digestive endoscopies. Arq Gastroenterol Y. 2007; 44(1): 14-17. https://doi.org/10.1590/S0004-28032007000100004
3. Freeman HJ. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polypsis. World J Gastroenterol. 1997; 9:1858-1860.
4. Raghunath AS, O'Morain C and McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005; 22(Suppl 1):55-63. https://doi.org/10.1111/j.1365-2036.2005.02611.x
5. Wani ZA, Mir MM, Rather MK, Lone SN, Mir TA and Raina AA. Gastric Polyps in North India: Prevalence, Pattern and Beyond. Med J Gastroenterol. 2011; 13:532-539. https://doi.org/10.1007/s11894-011-0224-6
6. Wani ZA, Mir MM, Rather MK, Lone SN, Mir TA and Raina AA. Changing prevalence of fundic gland polyps and proton pump inhibitors. Asian J Med Sci. May 2021 | Vol 12 | Issue 5
7. Wani ZA, Mir MM, Raina AA, Lone SN and Taranum UM. Gastric Polyps in North India: Prevalence, Pattern and Beyond. Med J Gastroenterol. 2011; 13:532-539. https://doi.org/10.1007/s11894-011-0224-6
8. Goddard AF, Badreldin R, Pritchard DM, Walker MM and Sakamoto M, et al. β-Catenin mutations in sporadic fundic gland polyps. Virchows Archiv. 2001; 440:381-386. https://doi.org/10.1007/s004280100527
9. Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M, et al. β-Catenin mutations in sporadic fundic gland polyps. Virchows Archiv. 2001; 440:381-386. https://doi.org/10.1007/s004280100527
10. Weston BR, Helper DJ and Rex DK. Positive predictive value of endoscopic features deemed typical of gastric fundic gland polyps. J Clin Gastroenterol. 2003; 36:399-402. https://doi.org/10.1097/00004836-200305000-00007
11. Chandrasekharra V and Ginsberg GG. Endoscopic management of gastrointestinal stromal tumors. Curr Gastroenterol Rep. 2011; 13:532-539. https://doi.org/10.1007/s11894-011-0224-6
12. Susanne W. Carmack, Genta RM, Schuler CM and Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol. 2009; 104:1524-1532. https://doi.org/10.1038/aqj.2009.139
13. Cao H, Wang B, Zhang Z, Zhang H and Qu R. Distribution trends of gastric polyps: An endoscopy database analysis of 24 121 northern Chinese patients. J Gastroenterol Hepatol. 2012; 27:1175-1180. https://doi.org/10.1111/j.1440-2491.2012.07116.x
14. Lauwers GY, Carneiro F, Graham DY, Curado MP, Franceschi S, Montgomery E, et al. Gastric carcinoma. In: Haboubi N. Pathology and genetics: Tumours of the digestive system. Surg Oncol. 2000; 9:144-145. https://doi.org/10.1016/S0960-7404(01)00003-2
15. Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M, et al. β-Catenin mutations in sporadic fundic gland polyps. Virchows Archiv. 2001; 440:381-386. https://doi.org/10.1007/s004280100527
16. Stolte M, Sticht T, Eidt S, Ebert D and Finkenzeller G. Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy. 1994; 26:659-665. https://doi.org/10.1055/s-2007-1009601
17. Deppisch LM and Rona VT. Gastric epithelial polyps. A 10-year study. J Clin Gastroenterol. 1989; 11:110-115. https://doi.org/10.1097/00004836-198902000-00028
18. Roseau G, Druceux M, Molas G, Ponsot P, Amouyal P, Palazzo L, et al. Epithelial gastric polyps in a series of 13000 gastroscopies. Presse Med 1990; 19:650-654.
19. Peretz A, Fuchs T, Livovsky DM, Turvall E, Pappo O and Ackerman Z. The changing histological pattern of gastric polyps in an ethnically heterogeneous population. Scand J Gastroenterol. 2012; 47:907-913. https://doi.org/10.3109/00365521.2012.682091
20. Fan NN, Yang J, Sun G, Lu ZS, Ling Hu EQ, Wang XD, et al. Changes in the spectrum of gastric polyps in the Chinese population. World J Gastroenterol. 2015;21(33):9758-9764. https://doi.org/10.3748/wjg.v21.i33.9758
21. Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ and Stehouwer CDA. Use of proton pump inhibitors and risk of fundic gland polyps and gastric cancer: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016; 14:1706-1719. https://doi.org/10.1016/j.cgh.2016.05.018
22. Choudhry U, Boyce HW and Coppola D. Proton Pump Inhibitor-Associated Gastric Polyps: A Retrospective Analysis of Their Frequency, and Endoscopic, Histologic, and Ultrastructural Characteristics. Am J Clin Pathol. 1998; 110:615-621. https://doi.org/10.1093/ajcp/110.5.615
23. Zelter A, Fernandez JL, Bilder C, Rodriguez P, Wonaga A, Dorado F, et al. S1082 Fundic Gland Polyps and Association with Proton Pump Inhibitor Intake: A Prospective Study in 1,780 endoscopies. Gastroenterology. 2009;31:684-690. https://doi.org/10.1053/j.gastro.2009.09.063
24. Cats A, Edschenk B, Bloemena E, Roosendaal R, Lindeman J, Biemond I, et al. Parietal cell protrusions and fundic gland cysts and non-PPI use groups with insignificant differences.
Wani, et al.: Changing Prevalence of Fundic Gland Polyps and Proton Pump Inhibitors

Ther. 2006; 24:1341-1348. https://doi.org/10.1111/j.1365-2036.2006.03127.x

26. Declich P, Tavani E, Bellone S, Porcellati M, Pastori L, Omazzi B, et al. Sporadic fundic gland polyps: what happened before? Gut. 2004; 53:1721.

27. Vieth M and Stolle M. Fundic Gland Polyps are not induced by Proton Pump Inhibitor Therapy. Am J Clin Pathol. 2001; 116:716-720. https://doi.org/10.1309/XFWR-LXAI-7TK1-N3Q8

28. Rubio CA. Plugs clog the glandular outlets in fundic gland polyps. Int J Clin Exp Pathol. 2010; 3:69-74.

29. Odze R, Marcial M and Antonioli D. Gastric fundic gland polyps: A morphological study including mucin histochemistry, stereometry, and MIB-1 immunohistochemistry. Hum Pathol. 1996; 27:896-903. https://doi.org/10.1016/S0046-8177(96)90215-4

30. Graham DY and Genta RM. Long-term proton pumps inhibitors use and gastrointestinal cancer. Curr Gastroenterol Rep. 2008; 10:543-547. https://doi.org/10.1007/s11894-008-0100-1

31. Kumar KR, Iqbal R, Coss E, Park C, Cryer B and Genta RM. Helicobacter gastritis induces changes in the oxyntic mucosa indistinguishable from the effects of proton pump inhibitors. Hum Pathol. 2013; 44:2706-2710. https://doi.org/10.1016/j.humpath.2013.07.015

32. Declich P, Belloni J, Tavani E, Omazzi B, Bortoli A, Devani M, et al. Fundic gland polyps and proton pump inhibitors: an obvious link, or an open question? Hum Pathol. 2014; 45:1122-1123. https://doi.org/10.1016/j.humpath.2013.11.020

33. Genta RM, Schuler CM, Robiou CI and Lash RH. No Association between Gastric Fundic Gland Polyps and Gastrointestinal Neoplastic in a Study of Over 100,000 Patients. Clin Gastroenterol Hepatol. 2009; 7:849-854. https://doi.org/10.1016/j.cgh.2009.05.015

34. Watanabe N. Regression of fundic gland polyps following acquisition of Helicobacter pylori Gut. 2002; 51:742-745. https://doi.org/10.1136/gut.51.5.742

Authors Contribution:
ZW, MM-Concept and design of the study, prepared first draft of manuscript; MM, AK, IB and SM-Interpreted the results; reviewed the literature and manuscript preparation; MM, AK, MR, SL and AR-Coordination, review of literature and manuscript preparation; ZA, MM-Statistically analysed and interpreted, preparation of manuscript and revision of the manuscript

Work attributed to:
Noora super-speciality, Hospital, Srinagar, Jammu Kashmir, India

Orcid ID:
Dr. Zeeshan Wani- https://orcid.org/0000-0002-1096-2874
Dr. Muzaffar Mir- https://orcid.org/0000-0002-0412-4364
Dr. Afaq Khan- https://orcid.org/0000-0001-5931-4969
Dr. Iqbal Baba- https://orcid.org/0000-0002-3302-4725
Dr. Showkat Mir- https://orcid.org/0000-0003-1761-1994
Dr. Majid Rather- https://orcid.org/0000-0001-7814-1928
Dr. Shaheen Lone- https://orcid.org/0000-0002-6550-8724
Dr. Akhter Raina- https://orcid.org/0000-0002-1965-8027

Source of funding: Nil, Conflict of Interest: None declared.